Larger scale MR studies, and other forms of pharmacoepidemiology, would help to further evaluate the role of statin exposure in PD risk and progression and assess the potential for neuroprotection from ApoA5 and / or ApoC3 modulation. The gene discussed is APOA5; the disease is Parkinson disease.